Purpose
The opportunity
Astral Systems are developing multi-state fusion (MSF) technology in its “compact fusion reactors”, enabling hospitals to house localised units to support cancer care.
Rationale
Why we invested
We backed Astral Systems due to the quality of the team, the purpose of the venture to revolutionise cancer detection and treatment, the traction so far and the scalable potential of the company.
We were also comforted by fellow investors, led by SpeedInvest, and co-led by Playfair VC; with strong participation from Silicon Roundabout Ventures.
Future
Use of funds
Astral is now proud to offer it’s first product, available for order today. The Mk1 MSF reactor has 10x greater output and 10x longer lifetime than the best performing compact neutron generators on the market.
The products benefit from recent breakthroughs in fusion physics and the innovation cycle is still within it’s early days.
Further reading
Links / News
2025 Feb 6th: Astral Systems announce closing of their seed round with AIB.
2025 Feb 6th: TechCrunch – Could this startup’s compact nuclear reactors revolutionise cancer detection?
Astral Systems
“The whole industry has been in sort of supply constraint historically because of this reliance on centralised reactors”.
Dr. Tom Wallace-Smith | CTO & Co Founder
Real impact. Real startups
Related investments
Discover the startups our members are backing across the South West and South Wales. Explore recent investments and see the impact we’re making.
Ready to shape the future together?
Back the South West and South Wales’ most ambitious founders and grow your portfolio with us. Whether you’re new or experienced, Angel Investors Bristol gives you the network, insight, and opportunities to make real impact.
